- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05260788
Mapping 3D Bladder
April 7, 2022 updated by: University Health Network, Toronto
Feasibility of Spatially Registered Endoscopy for Mapping Bladder Mucosal Disease Into Radiation Planning Morphologic Imaging
This is a single centre, single arm feasibility study assessing the feasibility of using computer vision methods to recreate the 3D bladder shape and to then map the cystoscopy images onto this bladder shape.
If feasible, this 3D reconstructed shape would be spatially registered to radiological images (CT, MR) that are then used during radiation treatment planning.
This analysis would not be used for making any clinical treatment decisions on the patient.
Study Overview
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with clinical suspicion or histologic diagnosis of bladder tumour suitable for endoscopic evaluation and intent to treat using external beam radiation therapy.
Description
Inclusion Criteria:
- 18 years of age or older.
- Clinical suspicion or histologic diagnosis of bladder tumour suitable for endoscopic evaluation.
- Intention to treat using external beam radiation therapy as part of standard of care.
- Ability to provide written informed consent to participate in the study.
Exclusion Criteria:
- Prior complete or partial radiation therapy to bladder.
- Contraindications to radiation therapy as determined by the treating physician.
- Concurrent illness or condition that precludes subject from undergoing endoscopy or CT scanning.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Video recording of Cystoscopy
Time Frame: At study completion, up to 2 years
|
To determine the feasibility of using bladder endoscopic video images to reconstruct the three-dimensional shape of the bladder based on computer visions methods that employ feature extraction and triangulation and to map the endoscopy images onto the recreated 3D surface.
|
At study completion, up to 2 years
|
Contouring of 3D bladder rendering
Time Frame: At study completion, up to 2 years
|
To determine the feasibility of contouring the mucosal disease on the 3D bladder rendering.
|
At study completion, up to 2 years
|
Registering bladder shape
Time Frame: At study completion, up to 2 years
|
To determine the feasibility of registering the bladder shape to a CT/MR scan of the patient using deformable shape methods.
|
At study completion, up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2022
Primary Completion (Anticipated)
March 1, 2024
Study Completion (Anticipated)
March 1, 2025
Study Registration Dates
First Submitted
January 28, 2022
First Submitted That Met QC Criteria
February 18, 2022
First Posted (Actual)
March 2, 2022
Study Record Updates
Last Update Posted (Actual)
April 14, 2022
Last Update Submitted That Met QC Criteria
April 7, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-5338
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Baylor College of MedicinePfizerTerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
Clinical Trials on Cystoscopy
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Lower Urinary Tract SymptomUnited States
-
Western University, CanadaCompletedBladder Cancer | Hematuria | Bladder DiseaseCanada
-
University of Wisconsin, MadisonCompletedUrination Disorders | Hematuria | Recurrent Urinary Tract Infection | Voiding DysfunctionUnited States
-
Medway NHS Foundation TrustCompletedUrinary Incontinence, UrgeUnited Kingdom
-
Medway NHS Foundation TrustWithdrawnOveractive Bladder | Urinary Incontinence | Voiding Dysfunction
-
University of OklahomaCompleted
-
Mansoura UniversityUnknownPain, Postoperative | Bladder Cancer | Flexible Cystoscopy | Non-muscle Invasive Bladder Cancer (NMIBC)Egypt
-
Nellie Medical, LLCUnknownBladder Infections and Inflammations
-
University of MinnesotaCompletedUrinary Tract InfectionsUnited States
-
AdventHealthCompleted